Trial Profile
A Phase 2, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX4211 in Subjects With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 27 Jun 2012 Results published in the Clinical Pharmacology and Therapeutics.
- 28 Jun 2010 Results were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).
- 21 Jun 2010 Results presented at the 92nd Annual Meeting of the Endocrine Society (ENDO 2010), according to a Lexicon media release.